Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alpha 1-Antitrypsin Deficiency

In brief

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.

Key facts

Study ID
NCT04167345
Run by
Vertex Pharmaceuticals Incorporated
People needed
48
Starts
2020-01-13
Expected to finish
2020-11-14
Last updated by the study team
2022-02-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.